

Protocol

Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

(20116)

Medical Benefit		Effective Date: 10/01/15	Next Review Date: 07/19
Preauthorization	No	Review Dates: 09/10, 07/11, 07/12, 05/13, 05/14, 05/15, 07/15, 07/16, 07/17, 07/18	

Preauthorization is not required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none">• With chronic wounds	Interventions of interest are: <ul style="list-style-type: none">• Platelet-rich plasma	Comparators of interest are: <ul style="list-style-type: none">• Standard wound care	Relevant outcomes include: <ul style="list-style-type: none">• Symptoms• Change in disease status• Morbid events• Quality of life• Treatment-related morbidity
Individuals: <ul style="list-style-type: none">• With acute surgical or traumatic wounds	Interventions of interest are: <ul style="list-style-type: none">• Platelet-rich plasma	Comparators of interest are: <ul style="list-style-type: none">• Standard wound care	Relevant outcomes include: <ul style="list-style-type: none">• Symptoms• Change in disease status• Morbid events• Quality of life• Treatment-related morbidity

DESCRIPTION

The use of blood-derived growth factor platelet-rich plasma (PRP) has been suggested as a treatment for wounds or other miscellaneous non-orthopedic conditions including but not limited to acute surgical and traumatic wounds and nonhealing ulcers.

SUMMARY OF EVIDENCE

For individuals who have chronic wounds or acute surgical or traumatic wounds who receive PRP, the evidence includes a number of small controlled trials. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. Current results of trials using PRP are mixed, and the studies are limited in both size and quality. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Use of platelet-rich plasma (i.e., autologous blood-derived preparations) is considered **investigational** for the

treatment of acute or chronic wounds, including surgical wounds and nonhealing ulcers.

POLICY GUIDELINES

Note: This protocol does not address becaplermin.

MEDICARE ADVANTAGE

For Medicare Advantage members there may be potential for benefit under coverage with evidence development (CED).

BACKGROUND

WOUND HEALING TREATMENT

Autologous platelet concentrate suspended in plasma, also known as PRP, can be prepared from samples of centrifuged autologous blood. Exposure to a solution of thrombin and calcium chloride degranulates platelets, releasing various growth factors, and results in the polymerization of fibrin from fibrinogen, creating a platelet gel. The platelet gel can then be applied to wounds or may be used as an adjunct to surgery to promote hemostasis and accelerate healing. In the operating room setting, PRP has been investigated as an adjunct to a variety of periodontal, reconstructive, and orthopedic procedures. For example, bone morphogenetic proteins are a transforming growth factor, and thus PRP has been used in conjunction with bone-replacement grafting (using either autologous grafts or bovine-derived xenograft) in periodontal and maxillofacial surgeries.

PRP is distinguished from fibrin glues or sealants, which have been used for many years as a surgical adjunct to promote local hemostasis at incision sites. Fibrin glue is created from platelet-poor plasma and consists primarily of fibrinogen. Commercial fibrin glues are created from pooled homologous human donors; Tisseel® (Baxter International) and Hemaseel® (Haemacure Corp.) are examples of commercially available fibrin sealants. Autologous fibrin sealants can also be created from platelet-poor plasma. This protocol does not address the use of fibrin sealants.

Wound Closure Outcomes

This protocol addresses the use of PRP for nonorthopedic indications, which include a number of wound closure-related indications.

For this review, the primary end points of interest for the study of wound closure are as follows, consistent with guidance from the U.S. Food and Drug Administration (FDA) for the industry in developing products for the treatment of chronic cutaneous ulcer and burn wounds¹:

1. Incidence of complete wound closure;
2. Time to complete wound closure (reflecting accelerated wound closure);
3. Incidence of complete wound closure following surgical wound closure;
4. Pain control

REGULATORY STATUS

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the

Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Blood products such as PRP are included in these regulations.

Under these regulations, certain products including blood products such as PRP are exempt and therefore, do not follow the traditional FDA regulatory pathway. To date, the FDA has not attempted to regulate activated PRP.²

Numerous PRP preparation systems have been cleared for marketing by the FDA through the 510(k) process. These devices are intended to concentrate patient plasma at the point of care during bone grafting procedures. The use of different devices and procedures can lead to variable concentrations of active platelets and associated proteins, increasing variability between studies of clinical efficacy.

RELATED PROTOCOLS

Bioengineered Skin and Soft Tissue Substitutes

Electrostimulation and Electromagnetic Therapy for Treating Wounds

Negative Pressure Wound Therapy in the Outpatient Setting

Orthopedic Applications of Platelet-Rich Plasma

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. U.S. Food and Drug Administration. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment. Rockville, MD: Food and Drug Administration; 2006 June.
2. U.S. Food and Drug Administration (FDA). Tissue and Tissue Products. 2016; <http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/>. Accessed December 21, 2017.
3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Becaplermin for wound healing. TEC Assessments. 1999;Volume 14:Tab 5.
4. Zhao XH, Gu HF, Xu ZR, et al. Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis. *Metabolism*. Oct 2014; 63(10):1304-1313. PMID 25060693
5. Margolis DJ, Bartus C, Hoffstad O, et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. *Wound Repair Regen*. Nov-Dec 2005;13(6):531-536. PMID 16283867

6. Rees RS, Robson MC, Smiell JM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. *Wound Repair Regen.* May-Jun 1999;7(3):141-147. PMID 10417749
7. Senet P, Vicaut E, Beneton N, et al. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial. *Arch Dermatol.* Aug 2011;147(8):926-930. PMID 21482863
8. Freedman BM, Oplinger EH, Freedman IS. Topical becaplermin improves outcomes in work related fingertip injuries. *J Trauma.* Oct 2005;59(4):965-968. PMID 16374289
9. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Growth factors for wound healing. *TEC Evaluations.* 1992;7:352-377.
10. Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds. *Transfus Apher Sci.* Apr 2004;30(2):145-151. PMID 15062754
11. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. *Plast Reconstr Surg.* Nov 2004;114(6):1502-1508. PMID 15509939
12. Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. *J Extra Corpor Technol.* Mar 2004;36(1):28-35. PMID 15095838
13. Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am J Sports Med.* Feb 2011;39(2):266-271. PMID 21051428
14. Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. *Vox Sang.* Aug 2009;97(2):110-118. PMID 19392780
15. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev.* Oct 17 2012;10:CD006899. PMID 23076929
16. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev.* May 25 2016(5):CD006899. PMID 27223580
17. Martinez-Zapata MJ, Marti-Carvajal A, Sola I, et al. Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review. *Transfusion.* Jan 2009;49(1):44-56. PMID 18954394
18. Carter MJ, Fylling CP, Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. *Eplasty.* Oct 2011;11:e38. PMID 22028946
19. Picard F, Hersant B, Bosc R, et al. The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: A review and a proposal for a new standard care. *Wound Repair Regen.* Sep 2015; 23(5):638-643. PMID 26019054
20. Escamilla Cardenosa M, Dominguez-Maldonado G, Cordoba-Fernandez A. Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. *J Tissue Viability.* Nov 29 2016. PMID 27955807
21. Zhou SF, Estrera AL, Loubser P, et al. Autologous platelet-rich plasma reduces transfusions during ascending aortic arch repair: a prospective, randomized, controlled trial. *Ann Thorac Surg.* Apr 2015;99(4):1282-1290. PMID 25661906
22. Serraino GF, Dominijanni A, Jiritano F, et al. Platelet-rich plasma inside the sternotomy wound reduces the incidence of sternal wound infections. *Int Wound J.* Jun 2015;12(3):260-264. PMID 23692143
23. El-Anwar MW, Nofal AA, Khalifa M, et al. Use of autologous platelet-rich plasma in complete cleft palate repair. *Laryngoscope.* Jul 2016;126(7):1524-1528. PMID 27075516
24. Sidman JD, Lander TA, Finkelstein M. Platelet-rich plasma for pediatric tonsillectomy patients. *Laryngoscope.* Oct 2008;118(10):1765-1767. PMID 18622315
25. Almdahl SM, Veel T, Halvorsen P, et al. Randomized prospective trial of saphenous vein harvest site infection after wound closure with and without topical application of autologous platelet-rich plasma. *Eur J Cardiothorac Surg.* Jan 2011;39(1):44-48. PMID 20634084
26. Kazakos K, Lyras DN, Verettas D, et al. The use of autologous PRP gel as an aid in the management of acute trauma wounds. *Injury.* Aug 2009;40(8):801-805. PMID 18703188

27. Marck RE, Gardien KL, Stekelenburg CM, et al. The application of platelet-rich plasma in the treatment of deep dermal burns: A randomized, double-blind, intra-patient controlled study. *Wound Repair Regen*. Jul 2016;24(4):712-720. PMID 27169627
28. Qaseem A, Humphrey LL, Forcica MA, et al. Treatment of pressure ulcers: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. Mar 03 2015;162(5):370-379. PMID 25732279
29. Association for the Advancement of Wound Care (AAWC). *Guideline of Pressure Ulcer Guidelines*. Malvern, PA: AAWC; 2010.
30. Association for the Advancement of Wound Care (AAWC). *International Consolidated Venous Ulcer Guideline (ICVUG)*. 2015; <https://aawconline.memberclicks.net/assets/appendix%20c%20guideline%20icvug-textformatrecommendations-final%20v42%20changessaved18aug17.pdf>. Accessed December 21, 2017.
31. National Institute for Health and Clinical Excellence (NICE). *Diabetic foot problems: prevention and management [NG19]*. 2016; <https://www.nice.org.uk/guidance/ng19>. Accessed December 21, 2017.
32. Centers for Medicare & Medicaid Services. *Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R3)*. 2012; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=260>. Accessed December 21, 2017.
33. Centers for Medicare & Medicaid Services (CMS). *CMS Manual System: Pub 100-3 Medicare National Coverage Determinations (Transmittal 127)*. 2010 Oct; <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R127NCD.pdf>. Accessed December 21, 2017.
34. Centers for Medicare & Medicaid Services. *Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds (CAG-00190R2)*. 2008; [https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=208&NcaName=Autologous+Blood+Derived+Products+for+Chronic+Non-Healing+Wounds+\(2nd+Recon\)&bc=gCAAAAAACAAAAA%3D%3D&](https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=208&NcaName=Autologous+Blood+Derived+Products+for+Chronic+Non-Healing+Wounds+(2nd+Recon)&bc=gCAAAAAACAAAAA%3D%3D&). Accessed December 21, 2017.
35. *National Coverage Determination (NCD) for Blood-Derived Products for Chronic Non-Healing Wounds (270.3)*, Implementation Date 7/1/2013.